Related Experiment Video

Updated: May 30, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Evolving molecular mechanism-based strategies for control of hepatocellular carcinoma

K Sato1, M Mori

  • 1Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. satoken@showa.gunma-u.ac.jp

Current Medicinal Chemistry
|August 25, 2011
PubMed

Insights

Hepatocellular carcinoma (HCC) treatment has advanced with molecularly targeted agents. Sorafenib, a multikinase inhibitor, is the first drug to significantly improve overall survival in advanced HCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally.
  • Advanced HCC has a poor prognosis, with limited efficacy of traditional chemotherapy.
  • Growing understanding of HCC's molecular pathogenesis fuels interest in targeted therapies.

Purpose of the Study:

  • To review the molecular pathogenesis, targets, and signaling pathways in HCC.
  • To summarize the current status of molecularly targeted agents in advanced HCC clinical development.
  • To detail the mechanisms of action for these novel agents.

Main Methods:

  • Comprehensive literature review of molecular pathogenesis and targeted agents in HCC.
  • Analysis of clinical trial data for molecularly targeted therapies in advanced HCC.
  • Examination of signal transduction pathways and their inhibition.

Main Results:

  • Sorafenib, an oral multikinase inhibitor, demonstrated improved overall survival in advanced HCC.
  • This marks the first agent to show a survival benefit in HCC, initiating a new therapeutic era.
  • Numerous novel molecularly targeted agents are currently in clinical trials for HCC.

Conclusions:

  • Molecularly targeted agents represent a promising new frontier in advanced HCC treatment.
  • Understanding molecular pathways is crucial for developing effective targeted therapies.
  • Ongoing clinical trials are evaluating various agents, offering hope for improved patient outcomes.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery07:25

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery

Published on: August 18, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...